
    
      Comparison a single intravitreal injection of 4.0 mg of triamcinolone acetonide and 1.25 mg
      of bevacizumab regarding the ability of central macular thickness reduction. Secondary
      objectives are analysis of Visual Outcomes and variations on Intraocular Pressure. The
      patients data were statistically analyzed if there was a 24 week follow up completed.
    
  